# Power and sample size calculations

Patrick Breheny

September 14

#### Introduction

- Last time we discussed testing whether two groups differ with respect to survival/hazard
- One reason such tests are useful is that they provide an objective criteria (statistical significance) around which to plan out a study: How many subjects do we need? How long will the study take to complete? This is our topic for today
- FYI: Our book doesn't really address this issue; today's lecture is largely derived from George and Desu (1974)'s classic paper on the subject

## Exponential approximation

- The main idea behind George & Desu's approach is to assume constant hazards (i.e., exponential distributions) for the sake of simplicity
- Further work by other authors has indicated that the power/sample size one obtains from assuming constant hazards is fairly close to the empirical power of the log-rank test, provided that the ratio between the two hazard functions is constant
- Typically in a power analysis, we are simply trying to find the approximate number of subjects required by the study, and many approximations/guesses are involved, so using formulas based on the exponential distribution is usually good enough

# Special case: No censoring

- Let us begin with the special case of no censoring
- If  $T_i \stackrel{\perp}{\sim} \operatorname{Exp}(\lambda)$  for  $i = 1, \ldots, d$ ,

$$L(\lambda) = \prod_{i} \lambda \exp(-\lambda t_i)$$
$$= \lambda^d \exp(-\lambda V),$$

where 
$$V = \sum_i t_i$$

- Note that
  - $\circ$  V is a sufficient statistic
  - $\circ V \sim \Gamma(d, \lambda)$

# Type 2 censoring

- Now let's consider what happens in the case of type II censoring: in particular, that we have an initial sample size n and follow d subjects to failure
- In this case,

$$T_{(1)} \sim \operatorname{Exp}(n\lambda)$$
 
$$T_{(2)} - T_{(1)} \sim \operatorname{Exp}((n-1)\lambda)$$
 
$$\cdots$$
 
$$T_{(j)} - T_{(j-1)} \sim \operatorname{Exp}((n-j+1)\lambda)$$
 for  $j=1,\ldots,d$ , with  $T_{(0)}=0$ 

# Normalized spacings

- Alternatively, let  $U_j = (n-j+1)(T_{(j)}-T_{(j-1)})$
- Now  $U_j \stackrel{\perp}{\sim} \mathrm{Exp}(\lambda)$ , and

$$L(\lambda) = \prod_{j} \lambda \exp(-\lambda u_{j})$$
$$= \lambda^{d} \exp(-\lambda V),$$

where 
$$V = \sum u_j$$

• Note that, once again, V is a sufficient statistic and follows a  $\Gamma(d,\lambda)$  distribution

#### Remarks

- The exponential distribution, therefore, has the somewhat remarkable property that we arrive at the exact same inference if we follow d subjects until all have failed or if we follow some larger number n until d have failed
- Thus, we can carry out our calculations ignoring censoring, provided that we think of the sample size we obtain as the number of *events* that must be observed in order to achieve the desired power
- This is incredibly convenient for sample size planning, as it allows one to completely separate treatment effect concerns from censoring concerns

8 / 23

## Exact vs. approximate results

- ullet Note that because the exact distribution of V is known and easy to work with, it is possible to carry out exact power and sample size calculations
- However, one can obtain much simpler, closed-form expressions through a normal approximation
- Personal opinion: In an actual data analysis, exact results are quite desirable, but in a power analysis, the inaccuracy of the approximation is typically a minor concern compared to all other potential sources of error that go into the calculation

#### Central limit theorem

- The exponential distribution has mean  $1/\lambda$  and variance  $1/\lambda^2$
- Thus, by the central limit theorem,

$$\bar{X} \sim N\left(\frac{1}{\lambda}, \frac{1}{n\lambda^2}\right)$$

• This result, however, is not particularly satisfactory due to the  $\lambda$  term in the variance, which means we will have to solve a nonlinear equation to determine power/sample size

## Log transform

- Consider instead the variance-stabilizing transformation  $g(x) = \log(x)$
- By the delta method,

$$\log \bar{X} \mathrel{\dot{\sim}} \mathbf{N}\left(-\log \lambda, \frac{1}{n}\right)$$

 In addition to the convenience of linearity, variance-stabilizing transformations also typically lead to more accurate normal approximations

## Two samples: Hazard ratio

- With these preliminaries out of the way, let's get to the actual business of comparing two samples
- Let  $X_i \stackrel{\perp}{\sim} \operatorname{Exp}(\lambda_1)$  and  $Y_i \stackrel{\perp}{\sim} \operatorname{Exp}(\lambda_2)$ , with  $X_i \coprod Y_i$
- We have

$$\log\left(\frac{\bar{Y}}{\bar{X}}\right) \sim \mathcal{N}\left(\log\Delta, \frac{1}{n_1} + \frac{1}{n_2}\right),$$

where  $\Delta = \lambda_1/\lambda_2$  is the hazard ratio

12 / 23

#### Power formula

• Thus, letting  $Z = \log(\bar{Y}/\bar{X})/\sqrt{1/n_1 + 1/n_2}$ , we have

Under 
$$H_0: Z \sim \mathrm{N}(0,1)$$

Under 
$$H_A:Z \sim \mathrm{N}(0,1) + \frac{\log \Delta}{\sqrt{\frac{1}{n_1} + \frac{1}{n_2}}}$$

- The critical value for Z is therefore  $CV = \Phi^{-1}(1 \alpha/2)$ , where  $\alpha$  is the type I error rate and  $\Phi$  is the CDF of the standard normal distribution
- ullet Without loss of generality, we can take  $\Delta>1$ , which yields

Power = 
$$1 - \Phi \left( \text{CV} - \log \Delta / \sqrt{1/n_1 + 1/n_2} \right)$$

## Sample size formula

• In order to solve for the sample size(s) that yield a power of  $1-\beta$ , we must solve for the values of  $n_1$  and  $n_2$  that satisfy the following equation:

$$z_{1-\alpha/2} = -z_{1-\beta} + \log \Delta / \sqrt{1/n_1 + 1/n_2},$$

where  $z_q$  is the qth quantile of the standard normal distribution

• In the special case of  $n=n_1=n_2$ , we therefore have

$$n = 2\frac{(z_{1-\alpha/2} + z_{1-\beta})^2}{(\log \Delta)^2}$$

as the per-group sample size

#### Remarks

- Note that we do not even need to specify  $\lambda_1$  and  $\lambda_2$  to calculate power and sample size: we only need their ratio,  $\Delta$
- Furthermore, note that for the exponential distribution, the median survival time is  $\lambda^{-1}\log 2$
- Thus, the effect size can be equivalently thought of as a ratio
  of median survival times, rather than a hazard ratio, which in
  my experience is convenient as non-statisticians typically
  prefer to think in terms of median survival times than hazards

### NSCLC study: Background

- To illustrate how these formulas are used in practice, I'll
  discuss the planning of a study at the Holden Cancer Center
  here at the University of Iowa that I was involved in
- The study was looking at progression-free survival (PFS) in patients with refractory non-small cell lung cancer
- Historically, the median PFS for these patients is around 2.5 months
- $\bullet$  The investigators hypothesized, however, that a novel combination of protein kinase inhibitors and a cytokines could extend PFS by 50%

#### Sample size

- A 50% increase in median PFS corresponds to  $\Delta=1.5$
- Thus, to achieve 80% power under 5% type I error rate control (these are typical numbers), we require

$$n = 2\frac{(1.96 + 0.84)^2}{(\log(1.5))^2}$$
$$= 95.5$$

events in each arm of the study

• The actual study, however, was only a "single-arm" study

### Single arm study

- In a single-arm study, one assigns all patients to the experimental therapy, with the intention of comparing it to historical controls
- The use of historical controls is clearly subject to all sorts of biases, and a randomized trial would be preferable
- However, single arm studies like this one are common in what is called "Phase II" of clinical trial research
- The goal of a Phase II study is to learn about the clinical efficacy of a treatment; if it appears promising, one would then continue on to a fully randomized trial in Phase III
- Note that for a single-arm study (treating the control group as a known constant), the number of events in the experimental arm is cut in half (i.e., the total sample size is cut by 3/4)

## Censoring and accrual

- In this study, since these are patients with very poor prognosis and a median PFS of only 2.5 months (or  $\approx 4$  months, if the treatment is effective), we anticipated that only a small fraction of patients would remain censored at the end of the study
- Specifically, we made an assumption of 20% censoring, and included the following language in the proposal:

Power calculations indicate that to achieve 80% power to detect a 50% increase in median PFS with a 5% type I error rate, 48 events must be observed. Allowing for a 20% censoring rate, we therefore plan to enroll 58 patients.

18 / 23

## Study duration

- The duration of a study is also an important concern in planning a study with a time-to-event outcome
- In the NSCLC study, the accrual rate was anticipated to be approximately 50 patients per year
- We therefore made the conservative estimate that we could enroll our 58 patients in 18 months, and that we should be able to conclude the whole study within 2 years

## Formal approach

- This represents a fairly informal approach to planning the duration of a study, but in this case, given the short anticipated times-to-event involved, I felt it was adequate
- One can also take a more rigorous approach to calculating the expected duration of a study
- To start, let (0,T] denote the "entry" or "accrual" period of the study, and  $(T,T+\tau]$  denote the follow-up period


## Formal approach (cont'd)

- One widely used approach (which is also the approach used by George & Desu) is to use the fact that the expected number of patient-years necessary to observe d events is  $d/\lambda$
- Furthermore, letting Y(t) denote the number of patient-years accumulated by time t and a denote the average accrual rate,

$$\mathbb{E}Y(t) = a \int_0^{t^*} \int_0^{t-v} S(u) \, du \, dv$$
$$= \frac{at^*}{\lambda} \left\{ 1 - (\lambda t^*)^{-1} e^{-\lambda t} (e^{\lambda t^*} - 1) \right\}$$

where  $t^* = \min(T, t)$ 

# NSCLC study duration: Accrual 50 / year



## 50 random instances at 50 / year, T=1.5

